about
Bleeding related to disturbed fibrinolysisExamining thrombin hydrolysis of the factor XIII activation peptide segment leads to a proposal for explaining the cardioprotective effects observed with the factor XIII V34L mutationThe investigation and management of neonatal haemostasis and thrombosisFibrin stabilization (factor XIII), fibrin structure and thrombosisInterleukin-1 induces pro-mineralizing activity of cartilage tissue transglutaminase and factor XIIIaIdentification of an inframe deletion and a missense mutation in the factor XIIIA gene in two Turkish patients.Mutations in coagulation factor XIII A gene in three Turkish patients: two novel mutations and a known insertion.Safety of Factor XIII Concentrate: Analysis of More than 20 Years of Pharmacovigilance DataIdentification of a new Leu354Pro mutation responsible for factor XIII deficiency.Factor XIII deficiency associated with valproate treatment.Perinatal management of newborns with haemophilia.Recommendations for the transfusion management of patients in the peri-operative period. I. The pre-operative periodAutosomal recessive deficiencies of coagulation factors.Rare coagulation deficiencies.Surgery in severe factor XIII deficiency: report of a case of epilepsy neurosurgery and review.Factor XIII Transglutaminase Supports the Resolution of Mucosal Damage in Experimental Colitis.The rare coagulation disorders--review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation.Factor XIII (FXIII) and angiogenesis.Bruising and bleeding in infants and children--a practical approach.Roles of transglutaminases in cardiac and vascular diseases.Nonclinical analysis of the safety, pharmacodynamics, and pharmacokinetics of plasma-derived human FXIII concentrate in animalsNew developments in the management of congenital Factor XIII deficiency.Prophylaxis of bleeding episodes and surgical interventions in patients with rare inherited coagulation disorders.Medical and Surgical Management of Postpartum Hemorrhage in a Woman with Factor XIII Deficiency.Transglutaminse 2 and EGGL, the protein cross-link formed by transglutaminse 2, as therapeutic targets for disabilities of old age.Diagnosis and management of bleeding disorder in a child.Arg77His and Trp187Arg are the most common mutations causing FXIII deficiency in Iran.Difficulties and pitfalls in the laboratory diagnosis of bleeding disorders.Biology of Factor XIII and clinical manifestations of Factor XIII deficiency.Tissue-regenerating functions of coagulation factor XIII.A child with acquired factor XIII deficiency: case report and literature review.Congenital factor XIII deficiency in women: a systematic review of literature.The burden and management of FXIII deficiency.Morbidity and mortality in a large number of Iranian patients with severe congenital factor XIII deficiency.Diagnosis of factor XIII deficiency.In vitro secretion deficits are common among human coagulation factor XIII subunit B missense mutants: correlations with patient phenotypes and molecular models.Clinical and prognostic role of plasma coagulation factor XIII activity for bleeding disorders and 6-year survival in patients with chronic liver disease.Model thrombi formed under flow reveal the role of factor XIII-mediated cross-linking in resistance to fibrinolysisPharmacokinetics and safety of plasma-derived factor XIII concentrate (human) in patients with congenital factor XIII deficiency.Efficacy and safety of prophylactic treatment with plasma-derived factor XIII concentrate (human) in patients with congenital factor XIII deficiency.
P2860
Q28070127-F1452C47-B6CF-493B-B4C9-A1564731E016Q28115016-C9CA998B-F4EB-46FD-9D98-B8B551D21F8EQ28211888-AC520CF3-7C88-48A5-ABB0-FB58D015D360Q28305847-280B2F4F-2761-4BEC-8402-80C2E7369F77Q28343531-2295F401-6B04-4F3E-9097-D2FC18B34F00Q30164690-75F87E07-80DF-4481-8687-2DB4DE90ADA6Q30165321-AED59A38-CEC0-4DBA-BAC7-6D6E4563CB45Q31139049-2368DB0B-3395-42DE-9EB9-722626DF4AE7Q31899954-42E879A4-FE83-4EEA-A2AA-12DBF0C1989DQ33358677-A070CA9B-1A18-4E07-8C03-B9AB89F2815CQ34135323-6077EDC2-49C7-4F61-B042-84C25B903E6AQ34492729-A4B81971-E58D-4971-A1EB-44C1B34EA0D8Q34530397-10D46A74-46F9-4AC1-8F1B-2D9BB5562AD5Q34637015-6C85CAB2-7E86-4016-AD33-C6F1DF62E795Q35056874-CE5E9E0F-5148-4118-9498-8B2F2C2E3E26Q35670403-BC960997-1084-42A7-B2D0-33501650931DQ35882779-F864FB40-226C-4416-963D-6738EBFF98DCQ36243513-E2C1AD3E-16E5-44B0-81BF-26884C60898CQ36462083-5171F561-70D4-4981-983A-EF1184B246A6Q36664166-C66E901E-0759-40FF-8949-6177A66B71D5Q36719655-5A3E11EE-6E1F-4FB9-BBB0-9B971398DFE4Q36906072-EA336199-28E2-430F-86A5-46F2445C6F72Q37119660-5973C6A3-FFE7-4CC7-AE40-9E07B3D13E67Q37222828-8E81F70F-33B8-420E-8227-D71C9A45FAF0Q37406648-934EFC7A-21BA-40E8-9E79-9A683BA8C2EEQ37684558-E99888EC-18E3-4C0A-A112-363259810963Q37966812-640CF4C1-3038-4B53-A93F-72F1EA4BCD7BQ38020976-5232DB8F-144F-4BED-9D57-2CC757B7F579Q38038687-4DE377B8-3C21-442B-92C8-A4EBC9EFA382Q38081198-7C4AA577-6559-4C65-927A-EDB5FD45BF12Q38100849-BA29CBED-F6C2-4A01-941E-B8182D70FE38Q38132920-A12B6988-DF09-4317-99F9-848D2BEA497EQ38231336-80E4CC61-141E-4A8B-94DC-B2F784595313Q38675846-F633398D-91FD-4175-9CE9-68A44F805150Q38808158-B267B1AC-7956-4803-AB03-3E22B6F7FA08Q39115602-78E8804E-048A-4E4D-8E23-8C1327482E8DQ40354174-E514E6BB-2709-43F6-A7F7-89016429F6ACQ41904806-201C28A1-42B8-4B6A-9CEB-1EB9D5C256D9Q42178072-B7AF7890-F206-46A9-9408-C79B16AAB2ADQ42182012-0229B35E-ACDF-4A30-A219-FE1B1EE2E7D4
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Factor XIII deficiency.
@ast
Factor XIII deficiency.
@en
type
label
Factor XIII deficiency.
@ast
Factor XIII deficiency.
@en
prefLabel
Factor XIII deficiency.
@ast
Factor XIII deficiency.
@en
P2860
P1476
Factor XIII deficiency.
@en
P2093
Miloszewski KJ
P2860
P304
P356
10.1046/J.1365-2141.1999.01648.X
P407
P577
1999-12-01T00:00:00Z